CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Evaluate the results of genomic assays and other relevant patient- and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive, HER2-negative breast cancer.
  • Comprehend available research findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the current and future role of these agents as components of adjuvant treatment.
  • Review available clinical research findings documenting the efficacy of the addition of gonadotropin-releasing hormone agonists to standard adjuvant endocrine interventions for premenopausal patients with ER-positive breast cancer, and identify appropriate candidates for this strategy.
  • Recognize the potential for chemotherapy-induced premature ovarian insufficiency associated with various cytotoxic agents for breast cancer, and assess the effectiveness and possible role of various interventions in preserving ovarian hormone production and facilitating successful childbirth.
  • Consider available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibody-based approaches for localized triple-negative breast cancer, and develop a plan to integrate this therapeutic strategy into current treatment algorithms.
  • Appraise published efficacy and safety data with PARP inhibitors for localized breast cancer in patients harboring BRCA1/2 mutations, and consider how to optimally incorporate these agents in the curative setting where appropriate.
  • Evaluate the potential benefits of measuring circulating tumor DNA to assess the absence or presence of molecular residual disease during and after treatment for localized breast cancer, and consider the current and future utility of this strategy in clinical practice.
  • Assess early data with and ongoing clinical trials evaluating novel agents and treatment strategies under development for localized ER-positive and triple-negative breast cancer.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Harold J Burstein, MD, PhD
  Institute Physician, Dana-Farber Cancer Institute
  Professor of Medicine, Harvard Medical School
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  Matthew P Goetz, MD
  Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
  Professor of Oncology and Pharmacology
  Enterprise Deputy Director, Translational Research
  Director, Mayo Clinic Breast Cancer SPORE
  Mayo Clinic
  Rochester, Minnesota
  
  Consulting Agreements (Fees to Institution): ARC Therapeutics, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, Blueprint Medicines, Lilly, RNA Diagnostics, Sanofi, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Sermonix Pharmaceuticals; Data and Safety Monitoring Board/Committee: Seagen Inc; Moderator Service: Curio Science; Nonrelevant Financial Relationship: Clinical Education Alliance, Engage Health Media, JNCCN 360, Medscape, MJH Life Sciences, Total Health Conferencing.
  
  Sara A Hurvitz, MD, FACP
  Professor
  Senior Vice President
  Clinical Research Division
  Fred Hutchinson Cancer Center
  Head, Division of Hematology/Oncology
  UW Medicine
  Seattle, Washington
  
  Contracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celcuity, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Dignitana AB, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, GSK, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Orinove Inc, Orum Therapeutics, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Zymeworks Inc.
  
  Joyce O’Shaughnessy, MD
  Celebrating Women Chair in Breast Cancer Research
  Baylor University Medical Center
  Chair, Breast Disease Committee
  Sarah Cannon Research Institute
  Dallas, Texas
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Carrick Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Ontada, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc.
  
  Lajos Pusztai, MD, DPhil, FASCO
  Professor of Medicine
  Scientific Co-Director of the Center for Breast Cancer
  Co-Leader, Genetics, Genomics and Epigenetics Program
  Yale Cancer Center
  Yale School of Medicine
  New Haven, Connecticut
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exact Sciences Corporation, Merck, Natera Inc, Pfizer Inc, Predicine; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exact Sciences Corporation, Merck, Natera Inc, Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Lilly, Merck, Natera Inc, Novartis, and TerSera Therapeutics LLC.
  
  Release date: December 2023
  Expiration date: December 2024